On 17 November 2016 Mitsubishi Tanabe Pharma Corporation notified ICANN of its intent to terminate the .mtpc Registry Agreement entered into on 20 November 2014. Pursuant to Section 4.4(b) of the Registry Agreement, Registry Operator may terminate the Registry Agreement for any reason upon one hundred eighty (180) calendar day advance notice.

Pursuant to the terms of Section 4.5 of the Registry Agreement, ICANN consulted with Mitsubishi Tanabe Pharma Corporation to assess whether to transition operation of the .mtpc top-level domain (TLD) to a successor Registry Operator.

On 9 February 2017 ICANN made a preliminary determination that operation of the .mtpc TLD need not be transitioned to a successor Registry Operator based on the following rationale:

- Mitsubishi Tanabe Pharma Corporation, in its function as the Registry Operator has represented to ICANN that it does not sell, distribute or transfer control or use of any registrations in the .mtpc TLD to third parties.
- Registry Operator has represented to ICANN that it holds intellectual property rights for the name "mtpc".
- Two domain names are registered in the .mtpc TLD. Both domains are managed by the Registry Operator, including one as mandated by the Registry Agreement (nic.mtpc).
- Transitioning operation of the TLD is not necessary to protect the public interest.

On 11 March 2017 after a 30-day period for comments by interested parties, no comments were received. Pursuant to Section 4.4(b) of the Registry Agreement, ICANN will proceed to terminate the .mtpc Registry Agreement by 16 May 2017.